Satsuma Pharmaceuticals has registered an initial public offering, seeking to raise $75 million, according to a regulatory filing. The South San Francisco-based company is working on STS101, a nasal powder version of dihydroergotamine for migraine. It intends to use the money to fund its Phase 3 safety and efficacy clinical trials for STS101, manufacturing costs, […]
satsumapharmaceuticals
Satsuma raises $62 million for nasal drug delivery tech
Satsuma Pharmaceuticals has raised $62 million in a Series B preferred stock financing, led by Wellington Management. Other investors included RA Capital Management, TPG Biotech and Shin Nippon Biomedical. Osage University Partners, CAM Capital, Surveyor, Eventide Asset Management, Cormorant, Lumira Ventures and SBI Investment were new investors. Satsuma is working on a nasal powder version […]
